Clinical Updates and New Approaches: Ovarian Cancer, Head and Neck Cancer, and Adjuvant Therapy for Breast Cancer

Last Modified: November 13, 2003

Program Description and Objectives

As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to maintain an awareness and understanding of the vast array of therapeutic choices that is available is, at the very least, "daunting". The ASCO 2003 meeting featured over 3,600 abstracts covering preclinical and clinical developments for currently commercialized agents, as well as new agents not yet approved, across all tumor-types. The number of anticancer agents in clinical trials is estimated to exceed 400. There are limited opportunities for clinicians to hear key opinion leaders, specializing in all major oncology specialties, present cutting edge clinical information. Professional forums, such as ASCO and the Chemotherapy Foundation, provide rare opportunities for oncology professionals to hear, first-hand from investigators, the latest data and interpretation for cancer treatments spanning all major tumor-types.

The Chemotherapy Foundation Symposium (CFS) provides "coverage of emerging advances in the treatment of neoplastic diseases" and affords the opportunity "to learn about the new drugs, new modalities, current trials, new procedures and evolving developments in biotherapies". OncoLink will report on key presentations to enhance the learning opportunities of the oncology professional. This module will report on clinical updates and new approaches under investigation for the treatment of ovarian cancer and head and neck cancer, and adjuvant therapy for breast cancer.

After completing this program, participants will be able to:

  • Define how new therapeutic advances in ovarian cancer and head and neck cancer, and adjuvant therapy for breast cancer may be incorporated into patient care.
  • Identify new concepts in the treatment of ovarian cancer and head and neck cancer, and adjuvant therapy for breast cancer.
  • Describe new approaches under investigation that employ targeted therapies, with or without chemotherapy, for head and neck cancer and for adjuvant therapy for breast cancer.
  • Discuss the most recent clinical trials and their clinical implications for currently available chemotherapeutic agents in ovarian cancer.


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The American Academy of CME, Inc., is accredited by the ACCME to provide continuing medical education for physicians.


The American Academy of CME, Inc., designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Term of Approval

This educational activity has been approved through November 2004.

Faculty Disclosures

  • Tate Thigpen, M.D.
    Nothing to Disclose
  • Jonathan A. Ledermann, M.D.
    Nothing to Disclose
  • Robert F. Ozols, M.D., Ph.D.
    BMS - Research Support, Consultant
    Lilly - Research Support, Consultant
    Ortho Biotech - Research Support, Consultant
  • David Spriggs, M.D.
    Nothing to Disclose
  • Merrill S. Kies, M.D.
    Aventis - Speakers Bureau
    BMS - Research Support, Speakers Bureau
  • David M. Brizel, M.D.
    Ortho Biotech - Consultant, Speakers Bureau
    Amgen - Consultant
    Medimmune - Consultant
  • Paul E. Goss, M.D., Ph.D.
    Novartis - Research Support, Consultant
    Pfizer - Research Support, Consultant
    Schering - Research Support, Consultant
    AstraZeneca - Consultant
    Lilly - Consultant
    Ortho Biotech - Consultant
  • Gini F. Fleming, M.D.
    Abbott - Research Support
    Lilly - - Research Support
    Genentech - Research Support
    Pfizer - Consultant
  • Nuhad K. Ibrahim, M.D.
    Nothing to Disclose
  • Nicholas J. Robert, M.D.
    Nothing to Disclose

Instructions for Applying for CME

After reading all of the articles within this module you will be able to download the Program Evaluation (a PDF file), which you can print out. In order to receive your CME certificate, please complete the form and mail or fax as shown on the form.

Certificates will be mailed 6 to 8 weeks following receipt of your evaluation.

Ovarian Cancer
First Line Therapy Of Ovarian Cancer: What Next?
Tate Thigpen, M.D.
Paclitaxel And Platinum Versus Platinum-Based Chemotherapy In Relapsed Ovarian Cancer: Icon 4
Jonathan A. Ledermann, M.D.
Update On GOG Studies In Ovarian Cancer
Robert F. Ozols, M.D.
Duration Of Therapy For Ovarian Cancer: How Long Is Enough?
David Spriggs, M.D.
Head And Neck Cancer
EGFR Inhibitors In Head And Neck Cancer
Merrill S. Kies, M.D.
Motexafin Gadolinium And Concurrent Chemoradiation In Head And Neck Cancer
David M. Brizel, M.D.
Breast Cancer Adjuvant Therapy: Trailbazers And Milestones
Cox 2/Hormonal Approaches For Treatment And Prevention Of Breast Cancer
Paul E. Goss, M.D., Ph.D.
Adjuvant Hormonal Therapy In Premenopausal Women
Gini F. Fleming, M.D.
Vaccines For Breast Cancer: Real Challenge Or Reality?
Nuhad K. Ibrahim, M.D.
Adding Carboplatin To Herceptin/Taxanes In Her2+ Breast Cancer: An Update
Nicholas J. Robert, M.D.